P2RY12 and acute coronary syndrome: The first trial to study the efficacy and safety of DPI in patients with cardiovascular diseases was the “Anti-Xa Therapy to Lower cardiovascular events in Addition to aspirin with/without thienopyridine therapy in Subjects with Acute Coronary Syndrome” (ATLAS ACS 2-TIMI 51) trial, which demonstrated that the addition of rivaroxaban (2.5 or 5 mg twice daily) to SAPT (low-dose aspirin) or DAPT (aspirin plus a P2Y12 inhibitor) reduced atherothrombotic risk in patients with a recent acute coronary syndrome compared with antiplatelet therapy alone [194].